open access

Vol 80, No 5 (2012)
ORIGINAL PAPERS
Published online: 2012-08-27
Submitted: 2013-02-22
Get Citation

The impact of timeliness of care on survival in non-small cell lung cancer patients

Elżbieta Radzikowska, Kazimierz Roszkowski-Śliż, Piotr Głaz
Pneumonol Alergol Pol 2012;80(5):422-429.

open access

Vol 80, No 5 (2012)
ORIGINAL PAPERS
Published online: 2012-08-27
Submitted: 2013-02-22

Abstract

Introduction: It is uncertain whether timeliness improves clinical outcomes in lung cancer patients. The goal of the study was to analyse the influence of patient’s and doctor’s delays on survival of unselected population of NSCLC patients.
Material and methods: From 1995 to 1998, 8705 squamous cell lung cancer patient’s and 1881 adenocarcinoma patient’s were registered in Pulmonary Outpatients Clinics in all parts of Poland and subsequently in National Tuberculosis and Lung Diseases Research Institute Register (NTLDRIR).
Results: The median time from first symptom(s) to the beginning of a treatment was 92 days (mean —138.5 days).The median waiting time between first symptom(s) and first visit to a doctor’s was 30 days (mean 57 days) and from first visit to a doctor’s to referral to a chest physician — was 17 days (mean 41days). Diagnosis of the NSCLC was established in a mean time of 71 days (median 40 days), but chest physician diagnosed patients in a mean time of 51days (median 28 days). The multivariate analysis revealed that ECOG performance status (PS) 2 (HR = 1.4) and 3+4 (HR = 2.23), clinical stage of the disease II (HR = 1.32), III (HR = 1.41), and IV (HR = 1.82) were independent negative predictors of survival. Non-surgically treated patients had worse prognosis than patients treated surgically (HR = 3.03). Lack of patient’s delay had a significant positive impact on survival (HR = 0.88), particularly for patients in PS 0+1 (HR = 0.9) and 3+4 (HR = 0.9). Lack of doctor’s delay was a negative predictive factor of survival (HR = 1.14). It was observed particularly in patients in performance status 2 (HR = 1.28).
Conclusions: The patient’s delay and lack of doctor’s delay had a negative impact on survival of NSCLC patients.

Abstract

Introduction: It is uncertain whether timeliness improves clinical outcomes in lung cancer patients. The goal of the study was to analyse the influence of patient’s and doctor’s delays on survival of unselected population of NSCLC patients.
Material and methods: From 1995 to 1998, 8705 squamous cell lung cancer patient’s and 1881 adenocarcinoma patient’s were registered in Pulmonary Outpatients Clinics in all parts of Poland and subsequently in National Tuberculosis and Lung Diseases Research Institute Register (NTLDRIR).
Results: The median time from first symptom(s) to the beginning of a treatment was 92 days (mean —138.5 days).The median waiting time between first symptom(s) and first visit to a doctor’s was 30 days (mean 57 days) and from first visit to a doctor’s to referral to a chest physician — was 17 days (mean 41days). Diagnosis of the NSCLC was established in a mean time of 71 days (median 40 days), but chest physician diagnosed patients in a mean time of 51days (median 28 days). The multivariate analysis revealed that ECOG performance status (PS) 2 (HR = 1.4) and 3+4 (HR = 2.23), clinical stage of the disease II (HR = 1.32), III (HR = 1.41), and IV (HR = 1.82) were independent negative predictors of survival. Non-surgically treated patients had worse prognosis than patients treated surgically (HR = 3.03). Lack of patient’s delay had a significant positive impact on survival (HR = 0.88), particularly for patients in PS 0+1 (HR = 0.9) and 3+4 (HR = 0.9). Lack of doctor’s delay was a negative predictive factor of survival (HR = 1.14). It was observed particularly in patients in performance status 2 (HR = 1.28).
Conclusions: The patient’s delay and lack of doctor’s delay had a negative impact on survival of NSCLC patients.
Get Citation

Keywords

NSCLC; patient’s delay; doctor’s delay; survival; treatment delay; prognosis

About this article
Title

The impact of timeliness of care on survival in non-small cell lung cancer patients

Journal

Advances in Respiratory Medicine

Issue

Vol 80, No 5 (2012)

Pages

422-429

Published online

2012-08-27

Bibliographic record

Pneumonol Alergol Pol 2012;80(5):422-429.

Keywords

NSCLC
patient’s delay
doctor’s delay
survival
treatment delay
prognosis

Authors

Elżbieta Radzikowska
Kazimierz Roszkowski-Śliż
Piotr Głaz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl